144 related articles for article (PubMed ID: 8590858)
1. Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease.
Clarke K; Grigg A
Leuk Lymphoma; 1995 Nov; 19(5-6):521-2. PubMed ID: 8590858
[No Abstract] [Full Text] [Related]
2. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
[TBL] [Abstract][Full Text] [Related]
3. [Cardiogenic shock during polychemotherapy in a patient with Hodgkin's disease].
Drzewoski J; Chojnowski K; Olszańska-Skorek T; Krykowski E
Kardiol Pol; 1986; 29(8):555-9. PubMed ID: 2435945
[No Abstract] [Full Text] [Related]
4. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease.
Aglietta M; Montemurro F; Fagioli F; Volta C; Botto B; Cantonetti M; Racanelli V; Teofili L; Ferrara R; Amadori S; Castoldi GL; Dammacco F; Levis A
Cancer; 2000 Jan; 88(2):454-60. PubMed ID: 10640980
[TBL] [Abstract][Full Text] [Related]
5. MOPP, ABVD, or both to treat Hodgkin's disease.
Aisenberg AC
N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
[No Abstract] [Full Text] [Related]
6. Long-term follow-up of survival in Hodgkin's lymphoma.
Canellos GP; Niedzwiecki D; Johnson JL
N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
[No Abstract] [Full Text] [Related]
7. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy.
Matthews JH
Lancet; 1993 Oct; 342(8877):988. PubMed ID: 7692199
[No Abstract] [Full Text] [Related]
8. [Results of the treatment of Hodgkin's disease stage III and IV using the ABVD and BACOP programs].
Leszko B; Słomkowski M; Przybyszewska M; Apel D; Pawelski S
Acta Haematol Pol; 1986; 17(3-4):81-90. PubMed ID: 2438894
[No Abstract] [Full Text] [Related]
9. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
Dotti G; Stella CC; Mangoni L; Cottafavi L; Caramatti C; Almici C; Rizzoli V
Haematologica; 1995; 80(2):142-5. PubMed ID: 7543069
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
Minuk LA; Monkman K; Chin-Yee IH; Lazo-Langner A; Bhagirath V; Chin-Yee BH; Mangel JE
Leuk Lymphoma; 2012 Jan; 53(1):57-63. PubMed ID: 21740297
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor.
Merdin A; Çakar MK; Dal MS; Mert D; Yıldız J; Başçı S; Bakırtaş M; Darçın T; Şahin D; Ulu BU; Yiğenoğlu TN; Batgi H; Tetik A; İskender D; Altuntaş F
J Oncol Pharm Pract; 2020 Jun; 26(4):929-932. PubMed ID: 31822199
[TBL] [Abstract][Full Text] [Related]
12. ABVD in the treatment of Hodgkin's disease.
Bonfante V; Santoro A; Viviani S; Valagussa P; Bonadonna G
Semin Oncol; 1992 Apr; 19(2 Suppl 5):38-44; discussion 44-5. PubMed ID: 1384143
[TBL] [Abstract][Full Text] [Related]
13. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
Ho P; Sherman P; Grigg A
Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
[TBL] [Abstract][Full Text] [Related]
14. Treatment of childhood Hodgkin's disease with chemotherapy alone. Experiences from the Royal Children's Hospital, Melbourne.
Ekert H
Cancer Treat Res; 1989; 41():241-6. PubMed ID: 2484293
[No Abstract] [Full Text] [Related]
15. Chemotherapy in the treatment of Hodgkin's disease.
Canellos GP; Come SE; Skarin AT
Semin Hematol; 1983 Jan; 20(1):1-24. PubMed ID: 6189191
[No Abstract] [Full Text] [Related]
16. Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
Anglin P; Strauss BA; Brandwein JM
Leuk Lymphoma; 1993 Nov; 11(5-6):469-72. PubMed ID: 7510192
[TBL] [Abstract][Full Text] [Related]
17. [The whole dose at once?].
Rodríguez García J; Ramos Ortega FJ; Sandoval Guerra V; García Sanz R
Sangre (Barc); 1996 Jun; 41(3):259. PubMed ID: 8755216
[No Abstract] [Full Text] [Related]
18. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.
Graczyk J; Cheung MC; Buckstein R; Chan K
Leuk Lymphoma; 2014 Jan; 55(1):56-62. PubMed ID: 23597142
[TBL] [Abstract][Full Text] [Related]
19. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report.
Joensuu H; Söderström KO; Nikkanen V
Cancer; 1986 Oct; 58(7):1437-40. PubMed ID: 2427187
[TBL] [Abstract][Full Text] [Related]
20. [Fibrosing alveolitis after combined radio- and chemotherapy. A case report].
Herrmann G; Hübner K
Onkologie; 1988 Jun; 11(3):142-4. PubMed ID: 2457859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
